Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
1.
Int Orthop ; 43(7): 1549-1557, 2019 07.
Article in English | MEDLINE | ID: mdl-30470866

ABSTRACT

Highly cross-linked ultrahigh molecular weight polyethylene (UHMWPE) was introduced to decrease wear debris and osteolysis. During cross-linking, free radicals are formed, making highly cross-linked polyethylene vulnerable to oxidative degradation. In order to reduce this process, anti-oxidant vitamin E can be incorporated in polyethylene. This review provides an overview of the effects of vitamin E incorporation on major complications in total joint arthroplasty: material failure due to oxidative degradation, wear debris and subsequent periprosthetic osteolysis, and prosthetic joint infections. Secondly, this review summarizes the first clinical results of total hip and knee arthroplasties with vitamin E incorporated highly cross-linked polyethylene. Based on in vitro studies, incorporation of vitamin E in polyethylene provides good oxidative protection and preserves low wear rates. Incorporation of vitamin E may have the beneficial effect of reduced inflammatory response to its wear particles. Some microorganisms showed reduced adherence to vitamin E-incorporated UHMWPE; however, clinical relevance is doubtful. Short-term clinical studies of total hip and knee arthroplasties with vitamin E-incorporated highly cross-linked UHMWPE reported good clinical results and wear rates similar to highly cross-linked UHMWPE without vitamin E.


Subject(s)
Antioxidants/pharmacology , Arthroplasty, Replacement/adverse effects , Biocompatible Materials/pharmacology , Joint Prosthesis/adverse effects , Polyethylenes/pharmacology , Vitamin E/pharmacology , Arthroplasty, Replacement/instrumentation , Biocompatible Materials/adverse effects , Humans , Immunity/drug effects , Infections/etiology , Materials Testing , Osteolysis/etiology , Oxidative Stress/drug effects , Polyethylenes/adverse effects , Prosthesis Design , Prosthesis Failure/drug effects , Prosthesis Failure/etiology , Prosthesis-Related Infections/etiology
2.
Clin Infect Dis ; 64(12): 1742-1752, 2017 Jun 15.
Article in English | MEDLINE | ID: mdl-28369296

ABSTRACT

BACKGROUND.: Streptococci are not an infrequent cause of periprosthetic joint infection (PJI). Management by debridement, antibiotics, and implant retention (DAIR) is thought to produce a good prognosis, but little is known about the real likelihood of success. METHODS.: A retrospective, observational, multicenter, international study was performed during 2003-2012. Eligible patients had a streptococcal PJI that was managed with DAIR. The primary endpoint was failure, defined as death related to infection, relapse/persistence of infection, or the need for salvage therapy. RESULTS.: Overall, 462 cases were included (median age 72 years, 50% men). The most frequent species was Streptococcus agalactiae (34%), and 52% of all cases were hematogenous. Antibiotic treatment was primarily using ß-lactams, and 37% of patients received rifampin. Outcomes were evaluable in 444 patients: failure occurred in 187 (42.1%; 95% confidence interval, 37.5%-46.7%) after a median of 62 days from debridement; patients without failure were followed up for a median of 802 days. Independent predictors (hazard ratios) of failure were rheumatoid arthritis (2.36), late post-surgical infection (2.20), and bacteremia (1.69). Independent predictors of success were exchange of removable components (0.60), early use of rifampin (0.98 per day of treatment within the first 30 days), and long treatments (≥21 days) with ß-lactams, either as monotherapy (0.48) or in combination with rifampin (0.34). CONCLUSIONS.: This is the largest series to our knowledge of streptococcal PJI managed by DAIR, showing a worse prognosis than previously reported. The beneficial effects of exchanging the removable components and of ß-lactams are confirmed and maybe also a potential benefit from adding rifampin.


Subject(s)
Arthritis, Infectious/drug therapy , Arthritis, Infectious/therapy , Prosthesis-Related Infections/therapy , Streptococcal Infections/therapy , Aged , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Arthritis, Infectious/microbiology , Arthritis, Infectious/mortality , Biofilms/drug effects , Debridement , Female , Humans , Internationality , Male , Prognosis , Prosthesis-Related Infections/drug therapy , Prosthesis-Related Infections/microbiology , Prosthesis-Related Infections/mortality , Retrospective Studies , Rifampin/administration & dosage , Rifampin/therapeutic use , Salvage Therapy , Streptococcal Infections/drug therapy , Streptococcus agalactiae/isolation & purification , Treatment Failure , beta-Lactams/administration & dosage , beta-Lactams/therapeutic use
3.
J Orthop Res ; 34(10): 1828-1837, 2016 10.
Article in English | MEDLINE | ID: mdl-26876651

ABSTRACT

Standard antibiotic therapy in osteomyelitis patients is of limited value when methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis (MRSE), or small-colony variants (SCV) are present. Far better results are obtained by local drug delivery of antibiotic combinations including rifampicin, using a suitable carrier. We therefore investigated release kinetics of antibiotics from biodegradable poly(trimethylene carbonate) (PTMC) and in vitro biofilm inhibition of MRSA, MRSE, and S. aureus SCV strains in the course of 24, 72, and 168 h treatment by PTMC, either unloaded, gentamicin-loaded, loaded with rifampicin and fosfomycin, or rifampicin and vancomycin. PTMC appeared to be a suitable carrier for rifampicin alone or in combination with other antibiotics. Biofilm colony forming units and metabolic activity measurement (MTT assay) demonstrated significant (p < 0.05) inhibition for all strains when PTMC loaded with rifampicin and vancomycin was employed, especially after 168 h treatment. Confocal laser scanning microscopy images showed similar qualitative results. PTMC loaded with only gentamicin did not show any inhibition. This exemplifies that PTMC loaded with rifampicin and vancomycin holds promise for the treatment of recalcitrant osteomyelitis. © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:1828-1837, 2016.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Biofilms/drug effects , Methicillin-Resistant Staphylococcus aureus/drug effects , Rifampin/administration & dosage , Vancomycin/administration & dosage , Dioxanes , Drug Carriers , Drug Therapy, Combination , Microbial Sensitivity Tests , Polymers
4.
FEMS Microbiol Rev ; 39(2): 234-45, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25725015

ABSTRACT

We summarize different studies describing mechanisms through which bacteria in a biofilm mode of growth resist mechanical and chemical challenges. Acknowledging previous microscopic work describing voids and channels in biofilms that govern a biofilms response to such challenges, we advocate a more quantitative approach that builds on the relation between structure and composition of materials with their viscoelastic properties. Biofilms possess features of both viscoelastic solids and liquids, like skin or blood, and stress relaxation of biofilms has been found to be a corollary of their structure and composition, including the EPS matrix and bacterial interactions. Review of the literature on viscoelastic properties of biofilms in ancient and modern environments as well as of infectious biofilms reveals that the viscoelastic properties of a biofilm relate with antimicrobial penetration in a biofilm. In addition, also the removal of biofilm from surfaces appears governed by the viscoelasticity of a biofilm. Herewith, it is established that the viscoelasticity of biofilms, as a corollary of structure and composition, performs a role in their protection against mechanical and chemical challenges. Pathways are discussed to make biofilms more susceptible to antimicrobials by intervening with their viscoelasticity, as a quantifiable expression of their structure and composition.


Subject(s)
Environmental Microbiology , Anti-Infective Agents/pharmacology , Biofilms/drug effects , Microbial Viability , Viscosity/drug effects
5.
Expert Opin Drug Deliv ; 10(3): 341-51, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23289645

ABSTRACT

INTRODUCTION: Chronic osteomyelitis, or bone infection, is a major worldwide cause of morbidity and mortality, as it is exceptionally hard to treat due to patient and pathogen-associated factors. Successful treatment requires surgical debridement together with long-term, high antibiotic concentrations that are best achieved by local delivery devices, either made of degradable or non-degradable materials. AREAS COVERED: Non-degradable delivery devices are frequently constituted by polymethylmethacrylate-based carriers. Drawbacks are the need to remove the carrier (as the carrier itself may provide a substratum for bacterial colonization), inefficient release kinetics and incompatibility with certain antibiotics. These drawbacks have led to the quest for degradable alternatives, but also devices made of biodegradable calcium sulphate, collagen sponges, calcium phosphate or polylactic acids have their specific disadvantages. EXPERT OPINION: Antibiotic treatment of osteomyelitis with the current degradable and non-degradable delivery devices is effective in the majority of cases. Degradable carriers have an advantage over non-degradable carriers that they do not require surgical removal. Synthetic poly(trimethylene carbonate) may be preferred in the future over currently approved lactic/glycolic acids, because it does not yield acidic degradation products. Moreover, degradable poly(trimethylene carbonate) yields a zero-order release kinetics that may not stimulate development of antibiotic-resistant bacterial strains due to the absence of long-term, low-concentration tail-release.


Subject(s)
Absorbable Implants , Anti-Bacterial Agents/administration & dosage , Drug Delivery Systems , Osteomyelitis/drug therapy , Animals , Dioxanes , Humans , Lactic Acid , Osteomyelitis/microbiology , Polyesters , Polymers , Polymethyl Methacrylate
6.
J Arthroplasty ; 28(2): 374.e5-8, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22810009

ABSTRACT

We present a rare case of an immunocompetent host who developed a Candida albicans-infected total hip prosthesis. The infection could not be eradicated with debridement and extensive antifungal therapy. Our patient first underwent a resection of the proximal femur and local treatment with gentamicin-loaded cement beads. In a second procedure, a handmade cement spacer impregnated with voriconazole, amphotericin B, and vancomycin was placed. After 3 months of additional systemic antibiotic therapy, the patient remained afebrile, and a tumor prosthesis was placed. Six years postoperatively, she is doing well, walking with a small limp and no signs of recurrent infection. This is the first report on elution of voriconazole and amphotericin B from bone cement delivered at clinically significant concentrations for at least 72 hours.


Subject(s)
Antifungal Agents/administration & dosage , Arthroplasty, Replacement, Hip/adverse effects , Candidiasis/therapy , Femoral Neck Fractures/surgery , Femur/surgery , Prosthesis-Related Infections/therapy , Aged , Anti-Bacterial Agents/administration & dosage , Bone Cements , Bone Transplantation , Candida albicans , Debridement , Device Removal , Female , Hip Prosthesis/adverse effects , Hip Prosthesis/microbiology , Humans , Periprosthetic Fractures/surgery , Prosthesis-Related Infections/microbiology , Reoperation
7.
J Biomed Mater Res A ; 100(12): 3220-6, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22733713

ABSTRACT

Cementless prostheses are increasingly popular in total hip arthroplasties. Therewith, common prophylactic measures to reduce the risk of postoperative infection like the use of antibiotic-loaded bone cements, will no longer be available. Alternative prophylactic measures may include the use of antibiotic-releasing coatings. Previously, we developed a gentamicin-releasing coating for cementless titanium hip prostheses and derived an appropriate dosing of this coating by adjusting the amount of gentamicin in the coating to match the antibacterial efficacy of clinically employed gentamicin-loaded bone cement. In this manuscript, we investigated two important issues regarding the prophylactic use of this 1 mg cm(-2) bioactive gentamicin-releasing coating in cementless total hip arthroplasty: (1) its ability to prevent bacterial growth in a geometrically relevant set-up and (2) its antibacterial spectrum. A geometrically relevant set-up was developed in which miniature titanium stems were surrounded by agar, contaminated with bioluminescent Staphylococcus aureus. Novel, bio-optical imaging was performed allowing noninvasive, longitudinal monitoring of staphylococcal growth around miniature stems with and without the gentamicin-releasing coating. Furthermore, the antibacterial efficacy of the gentamicin-releasing coating was determined against a wide variety of clinical isolates, including bioluminescent Staphylococcus aureus strains, using traditional zone of inhibition measurements. The gentamicin-releasing coating demonstrated a wide-spectrum of antibacterial efficacy and successfully prevented growth of bioluminescent staphylococci around a miniature stem mounted in bacterially contaminated agar for at least 60 h. This implies that the gentamicin-releasing coating has potential to contribute to the improvement of infection prophylaxis in cementless total hip arthroplasty.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bone Cements/pharmacology , Coated Materials, Biocompatible/pharmacology , Gentamicins/pharmacology , Hip Prosthesis/microbiology , Luminescent Measurements/methods , Optical Imaging/methods , Microbial Sensitivity Tests , Photons , Staphylococcus aureus/drug effects , Staphylococcus aureus/isolation & purification , Time Factors , Titanium/pharmacology
8.
J Orthop Res ; 30(3): 341-7, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21866572

ABSTRACT

Wear of metal-on-metal (cobalt-chromium, Co-Cr particles) and metal-on-polyethylene (ultra-high-molecular-weight polyethylene, UHMWPE particles) bearing surfaces in hip prostheses is a major problem in orthopedics. This study aimed to compare the influence of Co-Cr and UHMWPE particles on the persistence of infection. Bioluminescent Staphylococcus aureus Xen36 were injected in air pouches prepared in subcutaneous tissue of immuno-competent BALB/c mice (control), as a model for the joint space, in the absence or presence of Co-Cr or UHMWPE particles. Bioluminescence was monitored longitudinally up to 21 days, corrected for absorption and reflection by the particles and expressed relative to the bioluminescence found in the presence of staphylococci only. After termination, air pouch fluid and air pouch membrane were cultured and histologically analyzed. Bioluminescence was initially lower in mice exposed to UHMWPE particles with staphylococci than in mice injected with staphylococci only, possibly because UHMWPE particles initially stimulated a higher macrophage presence in murine air pouch membranes. For mice exposed to Co-Cr particles with staphylococci, bioluminescence was observed to be higher in two out of six animals compared to the presence of staphylococci alone. In the majority of mice, infection risk in the absence or presence of Co-Cr and UHMWPE particles appeared similar, assuming that the longevity of an elevated bioluminescence is indicative of a higher infection risk. However, the presence of Co-Cr particles yielded a higher bioluminescence in two out of six mice, possibly because the macrophage degradative function was hampered by the presence of Co-Cr particles.


Subject(s)
Chromium Alloys/adverse effects , Joint Prosthesis/microbiology , Polyethylenes , Staphylococcal Infections , Animals , Luminescent Measurements , Male , Mice , Mice, Inbred BALB C
9.
Int J Artif Organs ; 34(9): 759-65, 2011 Sep.
Article in English | MEDLINE | ID: mdl-22094554

ABSTRACT

PURPOSE: In the last decades, hip prostheses with a metal-on-metal (MOM) bearing have been implanted by orthopedic surgeons worldwide. However, concerns are now raised towards the metal particles and degradation products released by MOM-bearings into surrounding tissue, although effects of Co-Cr wear on infection are also unknown. Therefore, we here determine the viable volumes of staphylococcal biofilms formed on polystyrene in the absence and presence of Co-Cr particles and Co-Cr ions. METHODS: Three clinically derived and two commercially available staphylococcal strains were grown in the presence of 2 mg/mL Co-Cr particles or 1000/500 µg/L Co-Cr ions derived from Co-Cr salts or from particle supernatant, under static and dynamic growth conditions. A dynamic model simulates the conditions that apply for biofilm formation in the human body, as synovial fluid in mobile patients with hip prostheses is in constant motion with accompanying shear rates. Images of 24 h old biofilms were made with confocal laser scanning microscopy and analyzed with the mathematical computer program COMSTAT, yielding the biovolume of a biofilm. X-ray photoelectron spectroscopy was performed on the particles to study their elemental surface composition. RESULTS: Most isolates showed a tendency of reduced biofilm growth in the presence of Co-Cr particles compared to growth during exposure to metal ions, but this was only significant in one strain under the dynamic growth condition (Staphylococcus aureus 7388). Characterization of the outer surface of the particles revealed a Co-Cr oxide layer enriched by Mo relative to the bulk concentration. CONCLUSIONS: MOM bearings produce metal particles which were found to possess antibacterial characteristics under dynamic growth conditions. Further research is needed towards the clinical relevance of this finding.


Subject(s)
Biofilms/drug effects , Chromium Alloys/pharmacology , Hip Prosthesis/adverse effects , Prosthesis-Related Infections/prevention & control , Staphylococcus aureus/drug effects , Staphylococcus epidermidis/drug effects , Biofilms/growth & development , Chromium Alloys/chemistry , Humans , Microbial Viability/drug effects , Microscopy, Confocal , Microscopy, Electron, Scanning , Particle Size , Photoelectron Spectroscopy , Prosthesis Design , Prosthesis-Related Infections/microbiology , Staphylococcus aureus/growth & development , Staphylococcus epidermidis/growth & development , Stress, Mechanical , Surface Properties
11.
J Orthop Res ; 29(11): 1654-61, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21491478

ABSTRACT

Cementless prostheses are increasingly popular but require alternative prophylactic measures than the use of antibiotic-loaded bone cements. Here, we determine the 24-h growth inhibition of gentamicin-releasing coatings from grit-blasted and porous-coated titanium alloys, and compare their antibacterial efficacies and gentamicin release-profiles to those of a commercially available gentamicin-loaded bone cement. Antibacterial efficacy increased with increasing doses of gentamicin in the coating and loading with 1.0 and 0.1 mg gentamicin/cm(2) on both grit-blasted and porous-coated samples yielded comparable efficacy to gentamicin-loaded bone cement. The coating had a higher burst release than bone cement, and also inhibited growth of gentamicin-resistant strains. Antibacterial efficacy of the gentamicin coatings disappeared after 4 days, while gentamicin-loaded bone cement exhibited efficacy over at least 7 days. Shut-down after 4 days of gentamicin-release from coatings is advantageous over the low-dosage tail-release from bone cements, as it minimizing risk of inducing antibiotic-resistant strains. Both gentamicin-loaded cement discs and gentamicin-coated titanium coupons were able to kill gentamicin-sensitive and -resistant bacteria in a simulated prothesis-related interfacial gap. In conclusion, the gentamicin coating provided similar antibacterial properties to those seen by gentamicin-loaded bone cement, implying protection of a prosthesis from being colonized by peri-operatively introduced bacteria in cementless total joint arthroplasty.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bone Cements , Coated Materials, Biocompatible , Gentamicins/pharmacology , Hip Prosthesis/microbiology , Prosthesis-Related Infections/prevention & control , Alloys , Humans , In Vitro Techniques , Materials Testing , Microscopy, Electron, Scanning , Staphylococcal Infections/prevention & control , Staphylococcus aureus/drug effects , Staphylococcus aureus/growth & development , Titanium
12.
BMC Musculoskelet Disord ; 11: 258, 2010 Nov 10.
Article in English | MEDLINE | ID: mdl-21067595

ABSTRACT

BACKGROUND: Around about 1970, a gentamicin-loaded poly (methylmethacrylate) (PMMA) bone cement brand (Refobacin Palacos R) was introduced to control infection in joint arthroplasties. In 2005, this brand was replaced by two gentamicin-loaded follow-up brands, Refobacin Bone Cement R and Palacos R + G. In addition, another gentamicin-loaded cement brand, SmartSet GHV, was introduced in Europe in 2003. In the present study, we investigated differences in gentamicin release and the antibacterial efficacy of the eluent between these four cement brands. METHODS: 200 µm-wide gaps were made in samples of each cement and filled with buffer in order to measure the gentamicin release. Release kinetics were related to bone cement powder particle characteristics and wettabilities of the cement surfaces. Gaps were also inoculated with bacteria isolated from infected prostheses for 24 h and their survival determined. Gentamicin release and bacterial survival were statistically analysed using the Student's t-test. RESULTS: All three Palacos variants showed equal burst releases but each of the successor Palacos cements showed significantly higher sustained releases. SmartSet GHV showed a significantly higher burst release, while its sustained release was comparable with original Palacos. A gentamicin-sensitive bacterium did not survive in the high gentamicin concentrations in the interfacial gaps, while a gentamicin-resistant strain did, regardless of the type of cement used. Survival was independent of the level of burst release by the bone cement. CONCLUSIONS: Although marketed as the original gentamicin-loaded Palacos cement, orthopaedic surgeons should be aware that the successor cements do not appear to have the same release characteristics as the original one. Overall, high gentamicin concentrations were reached inside our prosthesis-related interfacial gap model. These concentrations may be expected to effectively decontaminate the prosthesis-related interfacial gap directly after implantation, provided that these bacteria are sensitive for gentamicin.


Subject(s)
Bone Cements , Gentamicins/pharmacokinetics , Methylmethacrylates , Models, Biological , Prostheses and Implants , Animals , Polymethyl Methacrylate/pharmacokinetics , Prosthesis-Related Infections/prevention & control , Staphylococcus/growth & development
13.
Acta Orthop ; 81(5): 526-34, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20860450

ABSTRACT

BACKGROUND AND PURPOSE: Joint replacement with metal-on-metal (MOM) bearings have gained popularity in the last decades in young and active patients. However, the possible effects of MOM wear debris and its corrosion products are still the subject of debate. Alongside the potential disadvantages such as toxicity, the influences of metal particles and metal ions on infection risk are unclear. METHODS: We reviewed the available literature on the influence of degradation products of MOM bearings in total hip arthroplasties on infection risk. RESULTS: Wear products were found to influence the risk of infection by hampering the immune system, by inhibiting or accelerating bacterial growth, and by a possible antibiotic resistance and heavy metal co-selection mechanism. INTERPRETATION: Whether or not the combined effects of MOM wear products make MOM bearings less or more prone to infection requires investigation in the near future.


Subject(s)
Arthroplasty, Replacement, Hip/adverse effects , Metals/adverse effects , Prosthesis-Related Infections/etiology , Alloys/adverse effects , Biofilms/drug effects , Biofilms/radiation effects , Drug Resistance, Bacterial/drug effects , Hip Prosthesis/adverse effects , Humans , Ions , Metals, Heavy/adverse effects , Particle Size , Prosthesis Design , Prosthesis Failure , Prosthesis-Related Infections/immunology , Prosthesis-Related Infections/microbiology , Risk Factors
14.
Acta Orthop ; 80(5): 508-13, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19916680

ABSTRACT

BACKGROUND AND PURPOSE: Commercial gentamicin-loaded bone cement beads (Septopal) constitute an effective delivery system for local antibiotic therapy. These beads are not available in all parts of the world, and are too expensive for frequent use in others. Thus, orthopedic surgeons worldwide make antibiotic-loaded beads themselves. However, these beads are usually not as effective as the commercial beads because of inadequate release kinetics. Our purpose was to develop a simple, cheap, and effective formulation to prepare gentamicin-loaded beads with release properties and antibacterial efficacy similar to the commercially ones. METHODS: Acrylic beads were prepared with variable monomer content: 100% (500 microL/g polymer), 75%, and 50% to increase gentamicin release through creation of a less dense polymer matrix. Using the optimal monomer content, different gel-forming polymeric fillers were added to enhance the permeation of fluids into the beads. Polyvinylpyrrolidone (PVP) 17 was selected as a suitable filler; its concentration was varied and the antibiotic release and antibacterial efficacy of these beads were compared with the corresponding properties of the commercial ones. RESULTS: Gentamicin release rate and the extent of release from beads prepared with 50% monomer increased when the PVP17 content was increased. Beads with 15 w/w% PVP17 released 87% of their antibiotic content. This is substantially more than the gentamicin release from Septopal beads (59%). Acrylic beads with 15 w/w% PVP17 reduced bacterial growth by up to 93%, which is similar to the antibacterial properties of the commercial ones. INTERPRETATION: A simple, cheap, and effective formulation and preparation process has been described for hand-made gentamicin-releasing acrylic beads, with better release kinetics and with antibacterial efficacy similar to that of the commercial ones.


Subject(s)
Bone Cements , Drug Carriers , Gentamicins/administration & dosage , Methylmethacrylates/administration & dosage , Biofilms , Drug Compounding/economics , Drug Compounding/methods , Drug Implants , Gentamicins/pharmacokinetics , Humans , Materials Testing , Methylmethacrylates/pharmacokinetics , Osteomyelitis/drug therapy , Osteomyelitis/prevention & control , Prosthesis-Related Infections/drug therapy , Prosthesis-Related Infections/prevention & control
15.
Acta Orthop ; 80(5): 514-9, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19916681

ABSTRACT

BACKGROUND AND PURPOSE: Many investigations on biodegradable materials acting as an antibiotic carrier for local drug delivery are based on poly(lactide). However, the use of poly(lactide) implants in bone has been disputed because of poor bone regeneration at the site of implantation. Poly(trimethylene carbonate) (PTMC) is an enzymatically degradable polymer that does not produce acidic degradation products. We explored the suitability of PTMC as an antibiotic releasing polymer for the local treatment of osteomyelitis. METHODS: This study addressed 2 separate attributes of PTMC: (1) the release kinetics of gentamicin-loaded PTMC and (2) its behavior in inhibiting biofilm formation. Both of these characteristics were compared with those of commercially available gentamicin-loaded poly(methylmethacrylate) (PMMA) beads, which are commonly used in the local treatment of osteomyelitis. RESULTS: In a lipase solution that mimics the in vivo situation, PTMC discs with gentamicin incorporated were degraded by surface erosion and released 60% of the gentamicin within 14 days. This is similar to the gentamicin release from clinically used PMMA beads. Moreover, biofilm formation by Staphylococcus aureus was inhibited by approximately 80% over at least 14 days in the presence of gentamicin-loaded PTMC discs. This is similar to the effect of gentamicin-loaded PMMA beads. In the absence of the lipase, surface erosion of PTMC discs did not occur and gentamicin release and biofilm inhibition were limited. INTERPRETATION: Since gentamicin-loaded PTMC discs show antibiotic release characteristics and biofilm inhibition characteristics similar to those of gentamicin-loaded PMMA beads, PTMC appears to be a promising biodegradable carrier in the local treatment of osteomyelitis.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Dioxanes/administration & dosage , Drug Carriers , Gentamicins/administration & dosage , Osteomyelitis/drug therapy , Polymers/administration & dosage , Prosthesis-Related Infections/drug therapy , Absorbable Implants , Anti-Bacterial Agents/pharmacokinetics , Biofilms , Bone Cements , Dioxanes/pharmacokinetics , Gentamicins/pharmacokinetics , Humans , Methylmethacrylate/administration & dosage , Methylmethacrylate/pharmacokinetics , Polymers/pharmacokinetics
16.
Biomaterials ; 30(27): 4738-42, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19500839

ABSTRACT

Biodegradable delivery systems that do not produce acidic compounds during degradation are preferred for local antibiotic delivery in bone infections in order to avoid adverse bone reactions. Poly(trimethylene carbonate) (PTMC) has good biocompatibility, and is such a polymer. The objective of this in vitro study was to explore the suitability of PTMC as an antibiotic releasing polymer for the local treatment of bone infections. Degradation behaviour and corresponding release profiles of gentamicin and vancomycin from slowly degrading PTMC168 and faster degrading PTMC339 discs were compared in the absence and presence of a lipase solution. Gentamicin release in the absence of lipase was diffusion-controlled, while vancomycin release was limited. Surface erosion of PTMC only occurred in the presence of lipase. Both antibiotics were released in high concentrations from PTMC in the presence of lipase through a combination of surface erosion and diffusion. This illustrates the major advantage of surface-eroding biodegradable polymers, allowing release of larger antibiotic molecules like vancomycin.


Subject(s)
Anti-Bacterial Agents/pharmacology , Dioxanes/chemistry , Drug Delivery Systems , Polymers/chemistry , Gentamicins/pharmacology , Lipase/metabolism , Microscopy, Electron, Scanning , Solutions , Surface Properties/drug effects , Vancomycin/pharmacology
17.
J Biomed Mater Res A ; 88(3): 711-6, 2009 Mar 01.
Article in English | MEDLINE | ID: mdl-18335532

ABSTRACT

Metal-on-metal (MOM) bearings involving cobalt-chromium (Co-Cr) alloys in total hip arthroplasties are becoming more and more popular due to their low wear. Consequences of corrosion products of Co-Cr alloys are for the most part unclear, and the influence of cobalt and chromium ions on biofilm formation has never been studied. Therefore, the aim of this study was to evaluate how Co-Cr ions affect bacterial growth, biofilm formation, and architecture. A collection of clinically isolated and commercially available bacterial strains were exposed to Co-Cr concentrations as found in serum and above as found in adjacent tissue. Planktonic growth of bacteria was inhibited by concentrations of 200,000/93,000 microg/L Co-Cr. Co-Cr concentrations up to 20/9.3 microg/L as reported to occur in serum revealed no consistent influence on biofilm formation, but higher concentrations of 200,000/93,000 microg/L significantly reduced Staphylococcus aureus and CNS biofilm formation. As indicated by confocal laser scanning microscopy, no dead bacteria were encountered in the biofilms, and the metal ion concentrations used must be classified as growth-inhibiting and not bactericidal. Long-term clinical data on infection rates for Co-Cr MOM-bearings are not yet available, but the current results suggest that Co-Cr ions may yield these prostheses less prone to biofilm formation and subsequent infection.


Subject(s)
Arthroplasty, Replacement, Hip , Biofilms , Chromium/pharmacology , Cobalt/pharmacology , Cations/chemistry , Chromium/blood , Chromium/chemistry , Cobalt/blood , Cobalt/chemistry , Microbial Viability/drug effects , Staphylococcus aureus/drug effects
18.
Clin Orthop Relat Res ; 466(6): 1492-8, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18338216

ABSTRACT

Bone cements loaded with combinations of antibiotics are assumed more effective in preventing infection than bone cements with gentamicin as a single drug. Moreover, loading with an additional antibiotic may increase interconnectivity between antibiotic particles to enhance release. We hypothesize addition of clindamycin to a gentamicin-loaded cement yields higher antibiotic release and causes larger inhibition zones against clinical isolates grown on agar and stronger biofilm inhibition. Antibiotic release after 672 hours from Copal bone cement was more extensive (65% of the clindamycin and 41% of the gentamicin incorporated) than from Palacos R-G (4% of the gentamicin incorporated). The higher antibiotic release from Copal resulted in a stronger and more prolonged inhibition of bacterial growth on agar. Bacterial colony counting and confocal laser scanning microscopy of biofilms grown on the bone cements suggest antibiotic release reduced bacterial viability, most notably close to the cement surface. The gentamicin-sensitive Staphylococcus aureus formed gentamicin-resistant small colony variants on Palacos R-G and therefore Copal more effectively decreased biofilm formation than Palacos R-G.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Biofilms , Bone Cements/pharmacokinetics , Clindamycin/pharmacokinetics , Gentamicins/pharmacokinetics , Polymethyl Methacrylate/pharmacokinetics , Diffusion , Solubility , Staphylococcus aureus/drug effects , Staphylococcus aureus/growth & development
19.
Acta Orthop ; 78(3): 299-308, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17611841

ABSTRACT

Biomaterial-related infection of joint replacements is the second most common cause of implant failure, with serious consequences. Chronically infected replacements cannot be treated without removal of the implant, as the biofilm mode of growth protects the bacteria against antibiotics. This review discusses biofilm formation on joint replacements and the important clinical phenomenon of small-colony variants (SCVs). These slow-growing phenotypic variants often remain undetected or are misdiagnosed using hospital microbiological analyses due to their unusual morphological appearance and biochemical reactions. In addition, SCVs make the infection difficult to eradicate. They often lead to recurrence since they respond poorly to standard antibiotic treatment and can sometimes survive intracellularly.


Subject(s)
Arthroplasty, Replacement/adverse effects , Bacterial Infections/diagnosis , Biofilms , Joint Prosthesis/microbiology , Prosthesis-Related Infections/diagnosis , Anti-Bacterial Agents/administration & dosage , Bacteria/genetics , Bacteria/growth & development , Bacterial Adhesion/drug effects , Bacterial Infections/drug therapy , Bacterial Infections/microbiology , Biofilms/drug effects , Biofilms/growth & development , Coated Materials, Biocompatible , Humans , Phenotype , Prosthesis Failure , Prosthesis-Related Infections/drug therapy , Prosthesis-Related Infections/microbiology , Recurrence , Staphylococcus aureus/genetics , Staphylococcus aureus/growth & development , Virulence Factors/biosynthesis
20.
J Antimicrob Chemother ; 58(6): 1287-90, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17041238

ABSTRACT

OBJECTIVES: Antibiotic-loaded bone cements are used for the permanent fixation of joint prostheses. Antibiotic-loaded cements significantly decrease the incidence of infection. The objective of this study was to investigate whether the viability of bacteria derived from patients with a prosthesis-related infection could be further decreased when antibiotic release from bone cements was combined with application of pulsed ultrasound. METHODS: Escherichia coli ATCC 10798, Staphylococcus aureus 7323, coagulase-negative staphylococci (CoNS 7368 and CoNS 7391) and Pseudomonas aeruginosa 5148 were grown planktonically in suspension and as a biofilm on three different bone cements: Palacos R without gentamicin as control, gentamicin-loaded Palacos R-G and gentamicin/clindamycin-loaded Copal. The viability of planktonic and biofilm bacteria was measured in the absence and presence of pulsed ultrasound for 40 h. RESULTS: Ultrasound itself did not affect bacterial viability. However, application of pulsed ultrasound in combination with antibiotic release by antibiotic-loaded bone cements yielded a reduction of both planktonic and biofilm bacterial viability compared with antibiotic release without application of ultrasound. CONCLUSIONS: This study shows that antibiotic release in combination with ultrasound increases the antimicrobial efficacy further than antibiotic release alone against a variety of clinical isolates. Application of ultrasound in combination with antibiotic release in clinical practice could therefore lead to better prevention or treatment of prosthesis-related infections.


Subject(s)
Anti-Bacterial Agents/metabolism , Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Biofilms/growth & development , Bone Cements/chemistry , Microbial Viability , Ultrasonics , Biofilms/drug effects , Clindamycin/pharmacology , Colony Count, Microbial , Gentamicins/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...